Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in a...
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
About this item
Full title
Author / Creator
Forns, Xavier , Lee, Samuel S , Valdes, Joaquin , Lens, Sabela , Ghalib, Reem , Aguilar, Humberto , Felizarta, Franco , Hassanein, Tarek , Hinrichsen, Holger , Rincon, Diego , Morillas, Rosa , Zeuzem, Stefan , Horsmans, Yves , Nelson, David R , Yu, Yao , Krishnan, Preethi , Lin, Chih-Wei , Kort, Jens J and Mensa, Federico J
Publisher
United States: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies. We aimed to assess the efficacy and safety of 12 weeks of coformulated glecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infec...
Alternative Titles
Full title
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1943079998
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1943079998
Other Identifiers
ISSN
1473-3099
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(17)30496-6
